# Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

> **NCT05724069** · PHASE2 · COMPLETED · sponsor: **Alfasigma S.p.A.** · enrollment: 17 (actual)

## Conditions studied

- Chronic Intestinal Pseudo-obstruction

## Interventions

- **DRUG:** Velusetrag 15 mg once daily for 4 weeks.
- **DRUG:** Placebo once daily for 4 weeks.

## Key facts

- **NCT ID:** NCT05724069
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-04-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724069, "Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05724069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*